Pages that link to "Q50429907"
Jump to navigation
Jump to search
The following pages link to cardiovascular agent (Q50429907):
Displayed 50 items.
- antiarrhythmic agent (Q241549) (← links)
- indomethacin (Q409231) (← links)
- beta-fructose 1,6-bisphosphate (Q414945) (← links)
- calcium channel blocker (Q421700) (← links)
- diltiazem (Q422229) (← links)
- ivabradine (Q425729) (← links)
- ATC code C (Q433932) (← links)
- antihypertensive drug (Q575890) (← links)
- Bathmotropic (Q810790) (← links)
- ranolazine (Q907104) (← links)
- perhexiline (Q1232737) (← links)
- Dromotropic (Q1260170) (← links)
- sclerosing agent (Q2093727) (← links)
- Cardiac stimulant (Q2845162) (← links)
- cardiotonic (Q2938102) (← links)
- vasoconstrictor agents (Q3359124) (← links)
- vasodilator agent (Q4008956) (← links)
- meldonium (Q4289752) (← links)
- alinidine (Q4726779) (← links)
- falipamil (Q5431893) (← links)
- list of cardiac pharmaceutical agents (Q6608816) (← links)
- lubeluzole (Q6695177) (← links)
- Category:Drugs acting on the cardiovascular system (Q6814492) (← links)
- potassium channel blocker (Q7234689) (← links)
- sodium channel blocker (Q7553303) (← links)
- Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence (Q24618313) (← links)
- Everolimus-eluting stents in interventional cardiology (Q24630321) (← links)
- Neuropsychiatric consequences of cardiovascular medications (Q24635624) (← links)
- Drug-eluting balloon catheters for lower limb peripheral arterial disease: the evidence to date (Q26747772) (← links)
- Effectiveness of Ivabradine in Treating Stable Angina Pectoris (Q26750710) (← links)
- Targeting heart failure with preserved ejection fraction: current status and future prospects (Q26752956) (← links)
- Critical Limb Ischemia: Current Trends and Future Directions (Q26767021) (← links)
- Addressing Major Unmet Needs in Patients with Systolic Heart Failure: The Role of Ivabradine (Q26773370) (← links)
- Reducing myocardial infarct size: challenges and future opportunities (Q26775395) (← links)
- Generic versus brand-name drugs used in cardiovascular diseases (Q26775920) (← links)
- Management of patients with Arrhythmogenic Right Ventricular Cardiomyopathy in the Nordic countries (Q26782057) (← links)
- Emerging treatment options to improve cardiovascular outcomes in patients with acute coronary syndrome: focus on losmapimod (Q26798359) (← links)
- Determinants of adherence to heart failure medication: a systematic literature review (Q27008211) (← links)
- The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction (Q27024279) (← links)
- Effective dosing of L-carnitine in the secondary prevention of cardiovascular disease: a systematic review and meta-analysis (Q27027544) (← links)
- taprostene (Q27088939) (← links)
- mioflazine (Q27271208) (← links)
- Targeting Nitric Oxide with Natural Derived Compounds as a Therapeutic Strategy in Vascular Diseases (Q28073279) (← links)
- Repurposing of approved cardiovascular drugs (Q28074453) (← links)
- Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm (Q28077186) (← links)
- Critical appraisal of paclitaxel balloon angioplasty for femoral-popliteal arterial disease (Q28080110) (← links)
- Challenges in acute heart failure clinical management: optimizing care despite incomplete evidence and imperfect drugs (Q28085736) (← links)
- S100A1: a multifaceted therapeutic target in cardiovascular disease (Q28288362) (← links)
- Effects of probucol on restenosis after percutaneous coronary intervention: a systematic review and meta-analysis (Q28546595) (← links)
- Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study (Q28677533) (← links)